

## Research on Chronic Diseases

# Opposite charges-electrostatic attraction: Mechanism for curing HIV/AIDS, COVID-19 and cancers



#### **Abstract**

It is already in literature that RNA viruses which include HIV and COVID-19 virus, have positive electrical charges while DNA viruses and abnormal (tumor and infected) cells are negatively charged, hence the hypothesis: Opposite charges-electrostatic attraction, mechanism for treating viral/abnormal cells diseases.Electrically charged medicines would adsorb onto viruses of opposite charges, thereby inhibiting first stage of viral replication and mopping extracellular viruses. Those positively charged, would additionally, adsorb onto abnormal cells to mop tumor-cells and destroy infected cells (unmasking intracellular pathogens). Molecules of aluminum-magnesium silicate (AMS), a WHO-approved medicine/ stabilizing agent (adjuvant) consist of nanoparticles with negative and positive ends. The nanoparticles` ultrasmall size (0.96 nm) would enable them reach all organs/tissues to mop viruses and abnormal cells. As adjuvant, AMS improves antimicrobials-efficacies for effective treatment of secondary infections and as a silicate, it enhances immunity. Mopping viruses/abnormal cells, unmasking "hidden infections", effectively treating secondary-infections and enhancing immunity would cure any viral/abnormal-cell disease including COVID-19, HIV/AIDS and cancers. Nigeria does not have natural AMS-deposits but we have aluminum silicate and magnesium silicate (WHO-approved medicines, too). So, we used these other solid minerals to synthesize an AMS-brand {Al4 (SiO4 ) 3 + 3Mg2 SiO4 2Al2 Mg3 (SiO4 )3 }. To make the un-absorbable Medicinal synthetic AMS (MSAMS) act systemically, glucose® is incorporated in its formulations, to convey the electrically charged nanoparticles across mucous membranes (active transportation) into blood for circulation to all organs/tissues. The MSAMS has proved effective against all viruses and abnormal cells tested (in vitro and/or in vivo) including HIV, COVID-19 and cancer-cells.

#### **Publications**

Electrostatic Attraction: Inhibitory-mechanism of The Medicinal Synthetic Aluminum-magnesium silicate against Electrically Charged Disease-agents (Human immune deficiency virus/Cancer-cells/Other viruses/Infected cells) and the Medicine's Adjuvant Effects – Review

HIV/AIDS Recovery Rates in Male and Female Patients, Treated with Medicinal synthetic Aluminum-magnesium silicate

Clinical Trial of Medicinal Synthetic Aluminum-Magnesium Silicate on Viral Loads and CD4-Lymphocytes Counts of HIV/AIDS Patients

Acquired Immune Deficiency Syndrome in Man and Animals—A Review

### Maduike C O Ezeibe

Michael Okpara University of Agriculture, Nigeria

#### **Biography**

Maduike Ezeibe holds PhD, from University of Nigeria, Nsukka. He is also a fellow, College of Veterinary Surgeons, Nigeria, specializing in laboratory animal medicine (using animals for medical-researches). From studying size and electrical charges on platelets of molecules of aluminum-magnesium silicate (AMS: a WHO approved medicine/ stabilizing agent) he came up with the theory of opposite charges electrostatic attraction as a mechanism of treatment for diseases caused by electrically charged agents (viruses and cancers/ infected cells). Since AMS is not found in Nigeria as a natural mineral resource, he also developed a reaction for aluminum silicate and magnesium silicate (WHOapproved medicinal solid minerals, found in Nigeria) to get The medicinal synthetic aluminum-magnesium silicate (MSAMS). He expressed the synthesis with an equation {Al4 (SiO4 )3 + 3Mg2 SiO4 2Al2 Mg3 (SiO4 )3 :}. The MSAMS has proved effective against all viruses and abnormal cells so far tested (in vitro and/or in vivo) including HIV, COVID-19 and cancers.



5th International Conference on Chronic Diseases | Webinar | April 26-27, 2021

Citation: Maduike C O Ezeibe, Opposite charges-electrostatic attraction: Mechanism for curing HIV/AIDS, COVID-19 and cancers, Chronic Diseases 2021, 5th International Conference on Chronic Diseases, Webinar, April 26-27, 2021, 05